By Tom Zanki (October 2, 2018, 8:08 PM EDT) -- Two biotechnology startups, both represented by Cooley LLP while Latham & Watkins LLP is advising their underwriters, launched initial public offerings on Tuesday that are estimated to raise $342 million, adding to a growing slate of companies planning to go public next week.
Cancer-focused Allogene Therapeutics told regulators it plans to offer 16 million shares priced between $16 and $18, raising $272 million at midpoint, while Equillium Inc. plans to offer 4.67 million shares priced between $14 and $16, raising $70 million at midpoint. Neither company has recurring revenues yet and are going public primarily to fund drugs under development, according...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!